Taysha Gene Therapies, Inc. (TSHA) Form 10-K Annual Reports
Taysha Gene Therapies, Inc. (TSHA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: TSHA
CIK: 1806310
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte & Touche LLP
Auditor SinceSince 12/31/2019 12:00:00 AM
Lead Engagement PartnerPatrick Conway
Audit LocationChicago, Illinois, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001231919-26-000928 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0000895421-26-000269 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001193125-26-344610 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001193125-26-344594 | View SEC Doc Filr Page |
| 4 | 2026-07-10 | 2026-07-10 | 4 Filing | 0001665124-26-000013 | View SEC Doc Filr Page |
| 144 | 2026-07-10 | — | 144 Filing | 0001974158-26-000076 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-24 | 8-K | 0001193125-26-282855 | View SEC Doc Filr Page |
| 424B5 | 2026-06-25 | — | 424B5 | 0001193125-26-282846 | View SEC Doc Filr Page |
| 424B5 | 2026-06-24 | — | 424B5 | 0001193125-26-281288 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-22 | 8-K | 0001193125-26-276738 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-06-01 | 4 Filing | 0001709418-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-06-01 | 4 Filing | 0001238120-26-000008 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-06-01 | 4 Filing | 0001891712-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-06-01 | 4 Filing | 0001777421-26-000005 | View SEC Doc Filr Page |
| 8-K | 2026-06-02 | 2026-06-01 | 8-K | 0001193125-26-253478 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000902664-26-002553 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001493215-26-000122 | View SEC Doc Filr Page |
| 10-Q | 2026-05-06 | 2026-03-31 | 10-Q | 0001193125-26-207666 | View SEC Doc Filr Page |
| 8-K | 2026-05-06 | 2026-05-06 | 8-K | 0001193125-26-207633 | View SEC Doc Filr Page |
| ARS | 2026-04-22 | 2025-12-31 | ARS | 0001193125-26-168538 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-22 | — | DEFA14A | 0001193125-26-168533 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-22 | 2026-06-01 | DEF 14A | 0001193125-26-168525 | View SEC Doc Filr Page |
| 4 | 2026-04-13 | 2026-04-10 | 4 Filing | 0001665124-26-000011 | View SEC Doc Filr Page |
| 144 | 2026-04-10 | — | 144 Filing | 0001974158-26-000040 | View SEC Doc Filr Page |
| 10-K | 2026-03-19 | 2025-12-31 | 10-K | 0001193125-26-115202 | View SEC Doc Filr Page |